Asahi Kasei Pharma Corporation
Fasudil is safe and effective for patients with acute ischemic stroke
Published in Physician Law Weekly, February 1st, 2006
"A multicenter, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of fasudil, a Rhokinase inhibitor (RKI), in the treatment of acute ischemic stroke," scientists in Japan wrote.
"A total of 160 patients, who were able to receive drug treatment within 48 h of acute ischemic stroke onset were enrolled," wrote M. Shibuya and colleagues, Asahi Kasei Pharma Corporation.
The authors explained, "Patients received either 60 mg fasudil or a placebo (saline) by intravenous injection over 60 min, twice daily for 14 days. The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
Source: Physician Law Weekly (2006-02-01)
More Articles from Physician Law Weekly
- Cephalon, Inc.
Agreement with Mylan announced regarding settlement of Provigil patent litigation - Decision Resources, Inc.
Research and advisory firm names its top five key healthcare events of 2005 - Kansas Coalition for Lifesaving Cures
Poll shows Kansans support stem cell research and oppose any state-level ban - Medicaid
Michigan governor signs Medicaid Whistleblower Protection Legislation - Medicare
Delmarva Foundation encourages consumers to report prescription drug benefit fraud - Osaka Police Hospital
Tricuspid isthmus measurement by MDCT yields information for successful ablation - More from this issue of Physician Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
